Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia

Blood Adv. 2020 Feb 11;4(3):525-529. doi: 10.1182/bloodadvances.2019000917.

Abstract

  1. Treatment of relapsed refractory T-PLL with venetoclax monotherapy results in only transient and minor clinical responses.

  2. In vitro analyses pre- and postvenetoclax indicate dual dependence on BCL2 and MCL1; combined BCL2 and MCL1 inhibition are synergistic.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis
  • Female
  • Humans
  • Leukemia, Prolymphocytic, T-Cell* / diagnosis
  • Leukemia, Prolymphocytic, T-Cell* / genetics
  • Middle Aged
  • Myeloid Cell Leukemia Sequence 1 Protein / genetics
  • Proto-Oncogene Proteins c-bcl-2 / genetics

Substances

  • Myeloid Cell Leukemia Sequence 1 Protein
  • Proto-Oncogene Proteins c-bcl-2